Sage Therapeutics (NASDAQ:SAGE) Downgraded by StockNews.com

StockNews.com lowered shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a hold rating to a sell rating in a research report report published on Friday morning. A number of other equities research analysts also recently weighed in on SAGE. Wedbush reissued a neutral rating and set a $24.00 target price on shares of Sage […]

Related Keywords

United States ,Canada ,China ,America ,Zurcher Kantonalbank Zurich Cantonalbank ,First Advisors Inc ,Sage Therapeutics Inc ,Scotiabank ,Sage Therapeutics Company Profile ,Nasdaq ,Quest Partners ,Royal Bank ,Needham Company ,China Universal Asset Management Co ,Sage Therapeutics ,Free Report ,Get Free Report ,Universal Asset Management ,Kantonalbank Zurich Cantonalbank ,First Advisors ,Sage Therapeutics Daily ,Nasdaq Sage ,Sage ,Medical ,Downgrade ,Stocknews Com ,